All In Biotech

Drug Trial Radar · NCT04051710

Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH

Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy and Safety of Beclomethasone Dipropionate Metered Dose Inhaler (Inhalation Aerosol) (0.04mg/ INH) in Male and/ or Female Subjects With Asthma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,550

Actual

Start

Mar 12, 2019

Primary completion

Aug 29, 2019

Study completion Dec 20, 2019

Sponsor

Lead sponsor
Aurobindo Pharma LtdIndustry
Sponsor type
Industry
First posted
Aug 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation Aerosol) 0.04 mg/ INH with the marketed QVAR® 40 mcg (Beclomethasone dipropionate hydrofluoroalkane (HFA)) and to demonstrate superiority of both active treatments over placebo.

Conditions

  • Bronchial Asthma

Interventions

  • Test ProductDrug

    Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg

  • Reference ProductDrug

    Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg

  • PlaceboDrug

    Placebo Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in FEV1 From Pre Dose to End of TreatmentTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maharashtra Medical Foundation Joshi Hospital

    Pune, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.